MelioLabs Inc.
Melio is developing a rapid, culture-free bloodborne pathogen testing platform integrating proprietary assays, microfluidics, and machine-learning. The company targets faster and more accurate infectious disease diagnoses, aiming to reduce antimicrobial misuse and address antibiotic resistance. The platform is designed for comprehensive, direct-from-blood detection of a broad spectrum of pathogens, with a focus on real-time adaptability to new and emerging threats. Melio's system is in development and not yet commercialized.
Industries
biotechnology
health-care
health-diagnostics
Nr. of Employees
small (1-50)
MelioLabs Inc.
Patents
Products
Bloodborne pathogen testing platform
A diagnostic platform in development that integrates proprietary assays, microfluidics, and AI analytics to rapidly identify pathogens and antimicrobial resistance markers directly from blood.
Bloodborne pathogen testing platform
A diagnostic platform in development that integrates proprietary assays, microfluidics, and AI analytics to rapidly identify pathogens and antimicrobial resistance markers directly from blood.
Expertise Areas
- Infectious disease diagnostics
- Bloodborne pathogen detection
- AI-driven clinical diagnostics
- Clinical assay development
Key Technologies
- DNA melting analysis
- Microfluidics
- Machine learning
- Direct-from-blood pathogen detection